An Open-Label Phase 1B/2 Study to Evaluate the Safety and Efficacy of Tabelecleucel in Combination with Pembrolizumab in Subjects with Platinum -pre-treated Recurrent /Metastatic Epstein-Barr Virus-Associated Nasopharyngeal Carcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Platinum-pre-treated, Recurrent/metastatic Epstein-barr Virus-associated Nasopharyngeal Carcinoma
  • Age: Between 12 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Incurable, locally recurrent or metastatic NPC 2) Subjects must have had prior receipt of platinum-containing regimen, either: a. For the treatment of recurrent or metastatic disease, or b. Experienced progression of disease within 6 months following completion of a platinum-based combination therapy as part of (neo)adjuvant chemotherapy 3) For all subjects: Agree to submit prior biopsy material, if available, for biomarker assessment

You may not be eligible for this study if the following are true:

  • 1) Disease that is suitable for local therapy administered with curative intent 2) Requires vasopressor or ventilator support 3) Received antithymocyte globulin or similar anti-T-cell antibody therapy = 4 weeks prior to Cycle 1 Day 1 4) Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 of study treatment.

If you are registered as a volunteer, please login to the dashboard to send referrals.